GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » COGS-to-Revenue

NeuroPace (NeuroPace) COGS-to-Revenue : 0.26 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeuroPace COGS-to-Revenue?

NeuroPace's Cost of Goods Sold for the three months ended in Mar. 2024 was $4.78 Mil. Its Revenue for the three months ended in Mar. 2024 was $18.12 Mil.

NeuroPace's COGS to Revenue for the three months ended in Mar. 2024 was 0.26.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NeuroPace's Gross Margin % for the three months ended in Mar. 2024 was 73.62%.

NeuroPace COGS-to-Revenue Historical Data

The historical data trend for NeuroPace's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace COGS-to-Revenue Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.28 0.26 0.26 0.29 0.26

NeuroPace Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.27 0.26 0.25 0.26

NeuroPace COGS-to-Revenue Calculation

NeuroPace's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=17.299 / 65.421
=0.26

NeuroPace's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4.781 / 18.124
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroPace  (NAS:NPCE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NeuroPace's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 4.781 / 18.124
=73.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NeuroPace COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeuroPace's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroPace (NeuroPace) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » COGS-to-Revenue
Comparable Companies
ZIMV OM BFLY SMLR MASS ALUR AXGN XTNT TELA CLPT ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
Website
https://www.neuropace.com
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Executives
Martha Morrell officer: Chief Medical officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd. 10 percent owner CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker director, officer: Chief Executive Officer ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley officer: General Counsel and Secretary C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade director 6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield director C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer director 9701 JERONIMO, IRVINE CA 92618
Evan Norton director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob director 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet director, officer: Chief Executive Officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043